Elanco (ELAN) director Kapila Anand converts fees into deferred stock units

Rhea-AI Filing Summary

Elanco Animal Health director defers fees into stock units. Director Kapila K. Anand converted a portion of her cash director fees into deferred stock units under Elanco's Directors' Deferral Plan on December 31, 2025. She received 381.1312 Deferred Stock Units, each economically equivalent to one share of Elanco common stock, based on the closing share price of $22.63 on the grant date. Following this transaction, she held a total of 8,894.7414 deferred stock units, which will be settled in Elanco common stock when she separates from the Board of Directors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anand Kapila K

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units(1)(2)	(3)	12/31/2025		A		381.1312		(1)	(1)	Common Stock	381.1312	$22.63(2)(3)	8,894.7414	D

Explanation of Responses:

1. Ms. Anand elected to defer her director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.

2. The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.

3. The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $22.63 on December 31, 2025.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Kapila K. Anand	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Elanco (ELAN) report for Kapila K. Anand?

Elanco reported that director Kapila K. Anand elected to defer a portion of her cash director fees into 381.1312 Deferred Stock Units under the company’s Directors' Deferral Plan on December 31, 2025.

How many Elanco deferred stock units does Kapila K. Anand own after this transaction?

After the reported transaction, Kapila K. Anand beneficially owned 8,894.7414 Deferred Stock Units, each tied to one share of Elanco common stock.

At what price were Kapila K. Anand’s Elanco deferred stock units calculated?

The number of Deferred Stock Units granted was determined by dividing the deferred cash compensation by the Elanco common stock closing price of $22.63 on December 31, 2025.

When will Kapila K. Anand’s Elanco deferred stock units be settled?

The Deferred Stock Units will be settled in shares of Elanco common stock upon her separation from the company’s Board of Directors, in accordance with the Directors' Deferral Plan.

Is Kapila K. Anand a director or officer of Elanco (ELAN)?

The filing identifies Kapila K. Anand as a director of Elanco Animal Health Inc., with the Form 4 filed for one reporting person.